Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib Plus Rituximab for EBV+ PTLD
- Status
- COMPLETED
- Phase
- PHASE2
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Retreatment Study With Bortezomib for Multiple Myeloma
- Status
- COMPLETED
- Phase
- N/A
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
- Status
- COMPLETED
- Phase
- N/A
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
- Status
- COMPLETED
- Phase
- N/A
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
- Status
- COMPLETED
- Phase
- N/A